InflaRx (Nasdaq: IFRX) is a clinical-stage biopharmaceutical company focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a. Complement C5a is a powerful inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. InflaRx was founded in 2007 and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI and New York, NY, USA. Source
No articles found.
Amgen is committed to unlocking the potential of biology for patients suffering fr...
Amgen is committed to unlocking the potential o...
Neurohacker Collective was founded in 2015 with the mission of creating best in cl...
Neurohacker Collective was founded in 2015 with...
HealthEquity provides a solution to an issue of growing importance to American fam...
HealthEquity provides a solution to an issue of...
Syneos HealthÂŽ (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solut...
Syneos HealthÂŽ (Nasdaq:SYNH) is the only fully...
We have used biochemical, molecular & cell biology and in vivo models to screen, i...
We have used biochemical, molecular & cell biol...
Liquidia is a late-stage clinical biopharmaceutical company focused on the develop...
Liquidia is a late-stage clinical biopharmaceut...
Concert Pharmaceuticals is a clinical stage biopharmaceutical company focused on a...
Concert Pharmaceuticals is a clinical stage bio...
Caladrius is a clinical-stage biopharmaceutical company committed to the developme...
Caladrius is a clinical-stage biopharmaceutical...
Viela is dedicated to the development and commercialization of novel, life-changin...
Viela is dedicated to the development and comme...
Theravance Biopharma is a diversified biopharmaceutical company with the core purp...
Theravance Biopharma is a diversified biopharma...
Join the National Investor Network and get the latest information with your interests in mind.